PD-1 is an inhibitory immune receptor, and in the tumour microenvironment, tumour cells, through the binding of PD-1 to its ligands PD-L1 and PD-L2, inhibit the immune response of T cells and evade immune system surveillance [8, 9]. The gene discussed is PDCD1LG2; the disease is neoplasm.